I
n patients receiving massive transfusion a high mortality rate has been described, both in the trauma and nontrauma setting. [1] [2] [3] Rose et al. 2 report an in-hospital mortality rate of 34% in a mixed patient population receiving massive transfusion. Halmin et al., 1 in a nationwide cohort study assessing the epidemiology of massive transfusion in Sweden and Denmark, report a 30-day mortality of 24.8%. 1 Turan et al. 3 investigated the mortality after massive transfusion in patients undergoing noncardiac surgery using the American College of Surgeons National Surgical Quality Improvement Program database. In this study, a postoperative 30-day mortality of 17% was found in patients undergoing massive transfusion. Common causes for massive hemorrhage in nontrauma patients are gastrointestinal bleeding, ruptured abdominal aortic aneurisms, as well as surgical or obstetrical bleeding. [4] [5] [6] [7] In the abovementioned cohort study conducted in Sweden and Denmark, massive transfusion was reported with an incidence of 2.5 (Sweden) and 4.5 (Denmark) per 10,000 person years. 1 Turan et al. 3 report massive transfusion in 7,485 of 917,651 patients in National Surgical Quality Improvement Program 2006 to 2009, corresponding to 0.8%. Most recent studies investigating the pathophysiology and treatment of hemorrhage focused on trauma patients. 4, [6] [7] [8] [9] [10] [11] However, major surgery for nontraumatic disease has been reported to be the most common cause of massive bleeding, followed by trauma and obstetric bleeding. Although the overall incidence of massive bleeding is relatively small, it remains an important source of mortality in nontrauma patients. 1, 3 The goal of massive transfusion protocols (MTP) is to rapidly provide blood products to hemodynamically unstable bleeding patients and to treat coagulopathy. This includes the availability of blood products in predefined ratios and the rapid transport and transfusion of these products. 12 Massive transfusion protocols have been successfully implemented in trauma patients and have been shown to improve outcomes in this patient population, 12 including lower mortality, 13 a lower risk of multiorgan failure, higher rate of fascial closure, 14 and decreased use of blood products. 15 The current guidelines of the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP), support the implementation of MTP in the early care of trauma patients. 16 In summary, massive transfusion is rare but associated with a high mortality rate in nontrauma patients. Taking into account the abovementioned improved outcomes related to MTP in trauma patients, nontrauma patients may benefit from MTP, too. The aim of this systematic review and meta-analysis was, therefore, to assess the use of MTP and its effect on outcomes in nontrauma patients. We hypothesized that the implementation of MTP in nontrauma patients with massive bleeding leads to improved survival.
METHODS
This is a systematic literature review and meta-analysis investigating the role of MTP in bleeding nontrauma patients. PRISMA guidelines 17, 18 were followed throughout the literature search, meta-analysis, reporting of the data, and discussion (Table 5) .
Literature Search
A systematic literature search was conducted using the National Library of Medicine's Medline database (PubMed). 19 The search strategy was based on the PICOS process. 20, 21 When possible, Medical Subject Headings (MeSH) 22 were used as search terms. The following search terms were used for the PubMed search:
• Only original research articles in English language were included. Exclusion criteria were articles including patients younger than 18 years and nonoriginal research articles, such as literature reviews and letters to the editor.
All abstracts of the articles found were screened. If the abstracts were relevant to the topic, the corresponding articles were included in the review. Articles relevant to the topic that were cited in articles found on PubMed using the above-named search terms were also included in the review, as well as articles that described MTP both trauma and nontrauma patients. 
Quality Assessment
The quality of the studies included in this systematic literature review and meta-analysis was assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies 23 with mortality as outcome measure.
Outcomes
The primary outcome assessed was the 24-hour and 1-month mortality. Secondary outcomes were the number of blood products transfused, including packed red blood cells (PRBC), fresh frozen plasma (FFP), and platelets (PLT), as well as transfusion ratios.
Statistical Analysis
Studies that compared the mortality rate of MTP and non-MTP groups in nontrauma patients specifically were included in the meta-analysis. The number of survivors and nonsurvivors in MTP and non-MTP groups reported in these studies was extracted for the meta-analysis.
Meta-analysis for the 24-hour and 1-month mortality was performed using a Mantel-Haenszel random effect model. The estimated effect size for the 24-hour and 1-month mortality was reported as odds ratio (OR) and 95% confidence interval (CI) for each study that compared MTP and non-MTP groups, as well as for the overall cohort. Heterogeneity of included studies was assessed using Cochran Q statistic and I 2 . 24, 25 No funnel plots were created due to the small number of studies included in meta-analysis.
Statistical analysis was performed using Review Manager (RevMan) Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
RESULTS

Articles Included
The literature search and included articles are outlined in Figure 1 . A total of 252 abstracts were screened. Twelve articles were found to be relevant to the topic. [4] [5] [6] [7] [8] [9] [10] [11] [26] [27] [28] [29] All articles were published between 2007 and 2017. Included studies enrolled a total of 2,475 patients. Of these, 1,620 were nontrauma patients (Table 1) .
Seven studies included both trauma and nontrauma patients. [4] [5] [6] [7] 9, 10, 29 The nontrauma groups in these studies were comprised of patients undergoing emergency or elective surgery, [4] [5] [6] [7] [8] [9] [10] 29 as well as patients with gastrointestinal bleeding, 4-7,9,29 obstetric hemorrhage, 4, 5, 7, 10, 29 and vascular emergencies. 4, 6, 7, 9, 29 In three of these seven studies, analysis was performed using a mixed trauma/nontrauma population, comprising 91%, 10 76%, 29 and 38.2% to 100% (range, six hospitals included) 5 nontrauma patients. In four studies, trauma and nontrauma patients were analyzed separaterly 4, 6, 7, 9 (Table 1 ). Five studies investigated nontrauma patients only. 8, 11, [26] [27] [28] Three studies focused on patients with bleeding due to obstetric complications only, 11, 26, 27 whereas Johansson et al. analyzed patients with massive bleeding after ruptured abdominal aortic aneurysm exclusively. 28 Martinez-Calle et al. 8 included nontrauma patients undergoing oncologic surgery, cardiovascular surgery, other surgery, and nonsurgical treatment for massive bleeding. **Mean ± SD. †Median (IQR). ‡Including 8 patients that were transfused off-protocol and were not included in the analysis. §Mean ± SEM. GIT, gastrointestinal tract; AAA, abdominal aortic aneurism; SBP, systolic blood pressure. Quality Assessment Table 4 shows the quality assessment of the studies included based on the NOS. None of the studies included used a matched study design or adjusted for confounders. Therefore, based on the criteria of the NOS, no study received stars for the comparability of the study groups. The studies by Chay et al., 5 Gutierrez et al., 27 and Goodnough et al. 26 did not receive stars for the outcome categories, as mortality was not reported as an outcome measure in these studies. Furthermore, the studies by Gutierrez et al. and Goodnough et al. did not include a control group and consequently did not receive a star in this category. In the studies by Chay et al. 5 and Johansson et al. 28 the number of survivors and death was not reported. These studies therefore did not receive stars for the adequacy of follow-up category.
Patient Characteristics
The majority of the patients included were male, ranging from 64.4% to 87.1%. 4, [6] [7] [8] [9] [10] 28 Exceptions were the studies assessing obstetric patients only. 11, 26, 27 The age of included patients ranged from 29.9 years to 73.0 years (Table 1) .
Three studies reported comorbidities of the patients included.
4,10,28 Balvers et al. 10 showed that 26% of patients before the introduction of a MTP and 25% of the patients after the introduction had no known comorbidities. The remaining patients suffered from cardiovascular (57% in both groups) or pulmonary disease (8% and 7%), bleeding diathesis (4% and 3%), and other comorbidities (5% and 8%). Johansson et al. 28 found comorbidities in 74% and 73% of patients before and after the implementation of a MTP, respectively. In the study by Baumann Kreuziger et al. 4 the mean overall APACHE II score was 27, while it was significantly lower in trauma than in nontrauma patients (25 vs. 29, p < 0.05). The other studies did not report comorbidities of included patients. [5] [6] [7] [8] [9] 11, 26, 27, 29 
Definition of Massive Transfusion
The definition of massive transfusion was given in 9 articles. [4] [5] [6] [7] [8] [9] [10] [11] 29 Massive transfusion was most commonly defined as the transfusion of 10 or more units of PRBC in the first 24 hours after hospital admission. [4] [5] [6] [7] 9, 29 Other definitions were the transfusion of 5 or more units of PRBC in the first 12 hours after hospital admission, 10 the replacement of the whole blood volume (7% of ideal body weight in adults) in a 24-hour period, 8 the replacement of 50% of the whole blood volume in a 3-hour period, 8 the loss of 1,500 mL or greater blood in 10 minutes, 8 or the transfusion of 4 or more units of PRBC.
11
Indications for Massive Transfusion
Indications for massive transfusion in nontrauma patients were bleeding during or after surgery (frequency reported as 11.2 to 82.2%), [4] [5] [6] [7] [8] [9] [10] 29 obstetrical bleeding (4.4 to 100%), 4, 5, 7, 10, 11, 26, 27, 29 gastrointestinal bleeding (20.0 to 66.7%), [4] [5] [6] [7] 9, 29 vascular emergencies (2.7 to 100%), 4, 6, 7, 9, 28, 29 or other reasons (13.0 to 17.8%). 4, 8, 10 Blood Product Transfusion
Transfused blood products are shown in Table 2 . Of the five studies that compared the number of transfused units of blood products in nontrauma patients before and after the implementation of a MTP, 6, 8, 10, 11, 28 four studies revealed no statistically significant difference of the number of transfused units of PRBC, FFP, and PLT. 6, 8, 10, 11 In the study investigating the implemantation of a transfusion protocol in patients with ruptured abdominal aortic aneurysms, a significantly higher number of FFP and PLT during surgery, but lower postoperative transfusion of PRBC, FFP and PLT were found after implementation of the protocol. 28 Transfusion ratios (FFP:PRBC, PLT:PRBC) were reported in nine studies. [4] [5] [6] [7] [8] [9] [10] [11] 29 Of these, five studies compared transfusion ratios in MTP and non-MTP groups.
6,8,10,11,29 Sinha et al. 29 reported significantly higher FFP:PRBC and PLT:PRBC transfusion ratios in the MTP group compared with the pre-MTP group. 29 In the study by Balvers et al. 10 a significantly higher proportion of patients in the MTP group received PRBC/FFP transfusion ratios of 1:1 or less compared to the pre-MTP group. 10 In the other three studies, no statistically significant difference of the transfusion ratios in the MTP and non-MTP groups was found 6, 8, 11 ( Table 2) . Overactivation of MTP, defined as the proportion of patients with MTP activation that received 10 units or less of PRBC, was reported in four studies. The rate of MTP overactivation Results of studies that reported mortality in nontrauma patients specifically.
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found in these studies was high, ranging from 53.8% to 65% 4, 6, 7, 9 ( Table 2) .
McDaniel et al. 6 analyzed the wasted units of blood products before and after the implementation of a MTP. A significantly increased waste of PLTs was observed in patients with MTP activation compared with patients without MTP activation (12.8% vs. 8.1%, p = 0.046).
Impact of MTP on Mortality
Four studies compared the 1-month mortality in patients with and without MTP activation 6, 8, 10, 28 Of these four studies, two studies found a significantly lower 30-day mortality in the MTP group compared with the non-MTP group (Martinez-Calle et al. : 34% vs. 56%, p = 0.02). In contrast, McDaniel et al. 6 found no significant difference of the 30-day mortality in the MTP group and non-MTP group (50.0% vs. 42.1%, p = 0.207). Likewise, the study by Balvers et al. 10 revealed no significant difference of the 28-day mortality after the implementation of a MTP (35% vs. 34%, p = 0.801) ( Table 3) .
Three studies compared the 24-hour mortality in MTP and non-MTP groups. In two of these three studies, the 24-hour mortality was not significantly different between the MTP and non-MTP group (McDaniel et al. 6 : 30.8% vs. 15.8%, p = 0.155; Balvers et al. 10 : 15% vs. 12%, p = 0.386). On the other hand, Martinez-Calle et al. 8 found a significantly lower 24-hour mortality in the MTP group compared to the non-MTP group (0.0% and 1.1% vs. 7.3% [two MTP groups], p = 0.002) ( Table 3) .
Meta-analysis included four studies that reported mortality of MTP and non-MTP groups in nontrauma patients specifically. 6, 8, 11, 28 Meta-analysis revealed no statistically significant effect of MTP on the 24-hour mortality rate (OR, 0.42; 95% CI, 0.01-16.62, p = 0.65) and 1-month mortality (OR, 0.56; 95% CI, 0.30-1.07, p = 0.08) (Fig. 2) .
DISCUSSION
The aim of this systematic literature review and meta-analysis was to find scientific evidence for the use of MTP in bleeding nontrauma patients. Twelve studies including patients with perioperative, gastrointestinal, and obstetrical bleeding, as well as bleeding from vascular emergencies, were assessed (Fig. 1) .
Two studies found a significantly lower mortality associated with the introduction of a MTP in bleeding nontrauma patients. 8, 28 In two other studies that analyzed mortality before and after the implementation of a MTP, no statistically significant effect of the introduction of a MTP on mortality was found. 6, 10 Furthermore, one study that found a lower mortality in the MTP group included patients with ruptured aortic aneurysm only, which is a distinct group of patients with a very high mortality and morbidity. 30, 31 On the other hand, meta-analysis including the same studies showed a trend toward a lower 1-month mortality rate. Based on these results it is possible that MTP may lower the mortality rate in bleeding nontrauma patients. Taking into account the small number of studies eligible for inclusion in meta-analysis, more statistical power is needed to confirm this hypothesis.
Another reason for the nonsignificant effect of MTP on mortality found in the current meta-analysis may be delayed MTP activation in the studies included. In major trauma patients, severe bleeding is anticipated and MTP are readily activated according to clearly defined criteria. 16 In nontrauma patients, the onset of bleeding may be more subtle, delaying the activation of MTP. Furthermore, well-defined criteria for N/A Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
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massive transfusion in nontrauma patients are lacking. Martinez et al. report proactive triggering of MTP in only 20% in nontrauma patients. In the other 80%, MTP was automatically activated by the blood bank after the transfusion of more than 8 units of PRBC. 8 In the study by McDaniel et al. MTP activation accelerated the delivery of FFP and PLTs. However, MTP activation was not associated with improved survival in this study. 6 Although one of the goals of MTP is to achieve higher plasma and PLTs to PRBC transfusion ratios, FFP:PRBC and/ or PLT:PRBC transfusion ratios did not meet the currently recommended ratios of 1:1:1 or 1:1:2 32 in four studies 8, 9, 11, 29 (Table 2 ). This finding is surprising, as with the introduction of a MTP, predefined ratios of blood products should be available for transfusion. 12, 15, [33] [34] [35] A possible explanation for the lower than recommended transfusion ratios in these studies may be a delayed MTP activation with unbalanced PRBC transfusion prior to the activation of the protocol. 8 A high rate of MTP overactivation was found in four studies. 4, 6, 7, 9 The identification of nontrauma patients that require MTP activation may be challenging as specific criteria are still lacking. In trauma patients, on the contrary, there are wellestablished criteria for massive transfusion and MTP activation, such as the ACS TQIP Best Practice Guidelines, 16 the Assessment of Blood Consumption score, [36] [37] [38] the Trauma Associated Severe Hemorrhage score, 39 the algorithm developed for combat casualty patients by McLaughlin and collegues, 40 the Revised Assessment of Bleeding and Transfusion score, 41 and the Massive Transfusion Score. 42 The absence of defined criteria for massive transfusion in nontrauma patients most likely explains the high overactivation rate in this patient population.
The study of McDaniel et al. 6 was the only one that analyzed the waste of blood products. An increased waste of PLTs was found after the introduction of a MTP. The waste of blood products associated with MTP could potentially be prevented, as unused blood products may be provided to other patients if they are returned promptly to the blood bank. 6 Furthermore, timely termination of the MTP once the endpoints of transfusion are achieved may reduce the waste of blood products. The ACS TQIP lists several criteria for the termination of MTP, including downgrading to goal-directed transfusion if bleeding has been controlled by surgery or angioembolization, further resuscitation is futile, and-in patients with no active bleeding-laboratory findings indicate adequate blood coagulation. 16 Although the ACS TQIP criteria for the termination of MTP were elaborated for trauma patients, they may also be useful in nontrauma patients. Further studies will need to evaluate the criteria for MTP termination in nontrauma patients specifically.
Nontrauma patients included in the current review had many comorbidities, especially from cardiovascular origin 4, 10, 28, 29 (Table 1) . Trauma patients are typically younger and have less comorbidities than the nontrauma patients included in the current review. Furthermore, trauma patients may bleed from multiple injuries, whereas bleeding is often localized in nontrauma patients, for example, in patients with gastrointestinal bleeding or bleeding during cardiovascular surgery. Both trauma and nontrauma patients may suffer from profuse bleeding due to coagulopathy. However, due to the abovementioned cardiovascular comorbidities, drug-induced coagulopathy is more likely in nontrauma than in trauma patients. 43 When extrapolating indications and goals of MTP from trauma to nontrauma patients, the different characteristics of these two patient populations need to be considered.
This systematic literature review and meta-analysis has several limitations. First, all studies were retrospective. Second, three studies analyzed mixed cohorts of nontrauma and trauma patients, 5, 10, 29 while others focused on a specific group of patients. 11, [26] [27] [28] Third, the total number of patients that were included in meta-analysis was relatively small, limiting the validity of the results. Fourth, the quality of the studies included varied and was poor in some studies (Table 4) . Fifth, MTPs, including the indication for MTP activation and predefined transfusion ratios, differed between the studies included. To take into account the heterogeneity of the studies included, only studies reporting outcomes of MTP and non-MTP groups in nontrauma patients specifically were included in the quantitative analysis. Furthermore, a random-effects model was chosen for metaanalysis.
CONCLUSION
Based on the current literature review and meta-analysis, there is limited evidence that the implementation of MTP may be associated with decreased mortality in nontrauma patients. Both, overactivation and an increased waste of blood products have been reported with the introduction of MTP. However, patient characteristics, as well as the indication and definition of MTP were highly heterogeneous in the available studies. Further prospective investigation into this topic is warranted. 
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